News
The FDA Just Approved a Game-Changing Therapy for Blindness
A decision on Spark Therapeutics' (NASDAQ: ONCE) vision-restoring gene therapy, Luxturna, was expected next month, but the Food and Drug Administration decided an early OK was warranted following....
New Gene Therapies Could Change Hemophilia Forever
At last week's American Society of Hemophilia conference, Spark Therapeutics (NASDAQ: ONCE) and BioMarin (NASDAQ: BMRN) presented promising data for gene therapy drugs that could change the way....
3 Top Pharmaceutical Dividend Stocks to Buy Now
Income investors have favored the pharmaceutical sector for decades. That makes sense since drugs tend to enjoy high margins and are needed in good times and bad. These factors allow pharma....
Why Riot Blockchain Stock Is Soaring... Again
Shares of Riot Blockchain (NASDAQ: RIOT) are up 15% as of 12:00 p.m. EST after the company announced it raised a fresh round of capital by selling stock and warrants in a private placement. A....
Why Juno Therapeutics Stock Fell Last Week
Juno Therapeutics (NASDAQ: JUNO) reported some pretty good data at last week's American Society of Hematology conference, but the stock bombed shortly after.In this clip from Industry Focus:....
Celgene Stock Up Huge On Exciting CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ: CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio (NASDAQ:....
Celgene Shareholders Excited by CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ: CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio (NASDAQ:....
Bitcoin Stocks: It's the Name That Counts
As the tech sector boomed during the late 1990s, shrewd companies quickly figured out how to send their share prices soaring. If they renamed their company to something that ended with ".com,"....
3 High-Yield Stocks Still Worth Buying
Who doesn't like free money? While they may be somewhat forgotten as the stock market hits seemingly one new high after another, high-yield dividend stocks play an important role in providing....
Why Novavax Stock Is Tumbling Today
Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be....
This Possible Dog of the Dow Just Got Even More Interesting
If you invest in the Dogs of the Dow every year, you could end up buying Pfizer (NYSE: PFE) on Jan. 1. The strategy calls for buying the top 10 highest dividend-yielding stocks in the Dow Jones....
3 Questions Keeping Juno Therapeutics' Investors Up at Night
Juno Therapeutics (NASDAQ: JUNO) soared ahead of the high-profile American Society of Hematology conference earlier this month, but it's been tough going for investors ever since. The sell-off in....
Is Aurinia Pharmaceuticals a Buy?
There's good news and bad news for Aurinia Pharmaceuticals (NASDAQ: AUPH) shareholders. Let's start with the good news. The company has had a fantastic 2017, with its stock price soaring more than....
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share....
Delivery Hero: Indiengeschäft wird verkauft
Der Online-Essenslieferant Delivery Hero meldet heute den Verkauf seiner Plattform „footpanda Indien“ an die indische Plattform Ola. Den Verkaufserlös erhält Delivery Hero in Ola-Anteilen. Damit....
Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today
Monday was another record-setting day for major benchmarks, which had solid gains of between 0.5% and 1%. Market participants were optimistic that they'll get the corporate tax cuts that they've....
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Controversial billionaire George Soros may no longer be actively managing his namesake fund, Soros Fund Management, but the fund's quarterly activity remains a focal point for investors. The Soros....
Why Riot Blockchain, Inc Stock Is Soaring on Monday
Shares of Riot Blockchain (NASDAQ: RIOT) are soaring, rising about 22% as of 12:30 p.m. EST. The company's soaring share price follows the launch of CME's bitcoin futures and a short-lived surge....
3 Growth Stocks to Own in 2018
With U.S. stocks at all-times highs, it can be a serious challenge to find growth vehicles that are still worth buying at these levels. To do so, I think investors may want to try to mine the....
Is Cara Therapeutics, Inc. a Buy?
Small-cap biotech Cara Therapeutics (NASDAQ: CARA) is working to commercialize a drug to combat pain -- but the stock has managed to inflict a different sort of suffering on its investors in....
The 5 Best-Selling Drugs of 2017
We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.Payers and patients across the....
The 3 Best Biotech Stocks of 2017
Biotech stocks rocked in 2017. At least a lot of them did. The SPDR S&P Biotech ETF has chalked up a gain of 40% with only a couple of weeks left in the year -- twice the return of the S&P....
Here's Why GlycoMimetics Could Become a Takeover Target
Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next....
3 Top Dividend Aristocrats to Buy for 2018
It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends....
Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?Actually, it's two: Johnson & Johnson....